O043 Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury

Abstract Introduction Complement activation is a key mechanism of Ischaemia reperfusion injury, with the alternative pathway driving damage in particular. The main regulator factor H. We hypothesised that homodimeric mini-factor H (HDM-FH; PMID:29588430) may protect transplanted kidneys from complement mediated when administered during normothermic perfusion machine perfusion. Methods Kidneys were retrieved female white landrace pigs following an optimised protocol. One kidney each pair was randomised to receive 5mg HDM-FH (∼8μg/mL). perfused at 37°C autologous blood for 6 hours. binding measured using ELISA and immunofluorescence. by quantifying Bb deposition tissue. ability inhibit serum haemolytic assays. Results 4mgs bound perfusate perfusion, <10% lost urine suggesting saturation achieved. within confirmed localised glomeruli increasing over time Alternative reduced receiving as demonstrated deposition. Fibrinogen also found colocalise C3 glomeruli. inhibits activity dose-dependent manor. Conclusion Infusion prior simulated transplant conditions other secondary negative outcomes organ. Therefore, organ highly likely help prolong graft survival after this will be assessed future studies.